Nan Sun 1 , Zhaoli Chen , Fengwei Tan , Baihua Zhang , Ran Yao , Chengcheng Zhou , Jiagen Li , Yibo Gao , Ziyuan Liu , Xiaogang Tan , Fang Zhou , Max Y F He , Kang Shao , Ning Li , Bin Qiu , Jian Sun , Yue Yu , Suya Wang , Yuda Zhao , Xuejiao Shi , Jie He Show Affiliations »
Abstract
Show RCT »
Hide RCT «
PURPOSE: Effective biomarkers for the diagnosis of non-small cell lung cancer (NSCLC) are needed. We previously showed that isocitrate dehydrogenase 1 (IDH1) is significantly increased in NSCLC tumors. This study aimed to examine the plasma levels of IDH1 in a large patient population to evaluate its effectiveness in NSCLC diagnosis. EXPERIMENTAL DESIGN: The plasma levels of IDH1, CA125, Cyfra21-1, and CEA were assayed by ELISA. Blood samples were obtained from 1,422 participants (943 patients with NSCLC and 479 healthy controls ). The samples were randomly divided into a training set and a test set. Receiver operating characteristic and binary logistic regression analyses were applied to evaluate diagnostic efficacy and establish diagnostic mathematical models. RESULTS: Plasma IDH1 levels were significantly higher in patients with NSCLCs than in healthy controls (P < 0.001). The diagnostic use of IDH1 in lung adenocarcinoma [area under curve (AUC): 0.858 and 0.810; sensitivity: 77.1% and 76.2%; specificity: 82.9% and 76.6%; in the training set and test set, respectively] was significantly greater than that of CA125, Cyfra21-1, or CEA (P < 0.001). The model combining IDH1 with CEA, CA125, and Cyfra21-1 was more effective for lung adenocarcinoma diagnosis than IDH1 alone (sensitivity and specificity in the training set: 75.8%, 89.6%; test set: 86.3%, 70.7%). In addition, the plasma levels of IDH1 could contribute to the diagnostic model of lung squamous cell carcinoma. CONCLUSIONS: IDH1 can be used as a plasma biomarker for the diagnosis of NSCLCs, particularly lung adenocarcinoma, with relatively high sensitivity and specificity. ©2013 AACR.
RCT Entities: Population
Interventions
Outcomes
PURPOSE: Effective biomarkers for the diagnosis of non-small cell lung cancer (NSCLC ) are needed. We previously showed that isocitrate dehydrogenase 1 (IDH1 ) is significantly increased in NSCLC tumors . This study aimed to examine the plasma levels of IDH1 in a large patient population to evaluate its effectiveness in NSCLC diagnosis. EXPERIMENTAL DESIGN: The plasma levels of IDH1 , CA125 , Cyfra21-1, and CEA were assayed by ELISA. Blood samples were obtained from 1,422 participants (943 patients with NSCLC and 479 healthy controls). The samples were randomly divided into a training set and a test set. Receiver operating characteristic and binary logistic regression analyses were applied to evaluate diagnostic efficacy and establish diagnostic mathematical models. RESULTS: Plasma IDH1 levels were significantly higher in patients with NSCLCs than in healthy controls (P < 0.001). The diagnostic use of IDH1 in lung adenocarcinoma [area under curve (AUC): 0.858 and 0.810; sensitivity: 77.1% and 76.2%; specificity: 82.9% and 76.6%; in the training set and test set, respectively] was significantly greater than that of CA125 , Cyfra21-1, or CEA (P < 0.001). The model combining IDH1 with CEA , CA125 , and Cyfra21-1 was more effective for lung adenocarcinoma diagnosis than IDH1 alone (sensitivity and specificity in the training set: 75.8%, 89.6%; test set: 86.3%, 70.7%). In addition, the plasma levels of IDH1 could contribute to the diagnostic model of lung squamous cell carcinoma . CONCLUSIONS: IDH1 can be used as a plasma biomarker for the diagnosis of NSCLCs , particularly lung adenocarcinoma , with relatively high sensitivity and specificity. ©2013 AACR.
Entities: Disease
Gene
Species
Mesh： See more »
Substances： See more »
Year: 2013
PMID： 24046070 DOI： 10.1158/1078-0432.CCR-13-0046
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531